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Abstract: The comprehensive assessment of the transplantable tumor (TT) proposed and included 
in the last Italian consensus meeting still deserve validation. All consecutive patients with 
hepatocellular carcinoma (HCC) listed for liver transplant (LT) between January 2005 and December 
2015 were post-hoc classified by the tumor/patient stage as assessed at the last re-staging-time (ReS-
time) before LT as follow: high-risk-class (HRC) = stages TTDR, TTPR; intermediate-risk-class (IRC) = 
TT0NT, TTFR, TTUT; low-risk-class (LRC) = TT1, TT0L, TT0C. Of 376 candidates, 330 received LT and 
46 dropped-out. Transplanted patients were: HRC for 159 (48.2%); IRC for 63 (19.0%); LRC for 108 
(32.7%). Cumulative incidence function (CIF) of tumor recurrence after LT was 21%, 12%, and 8% 
at 5-years and 27%, 15%, and 12% at 10-years respectively for HRC, IRC, and LRC (P = 0.011). IRC 
patients had significantly lower CIF of recurrence after LT if transplanted >2-months from ReS-time 
(28% vs 3% for <2 and >2 months, P = 0.031). HRC patients had significantly lower CIF of recurrence 
after-LT if transplanted <2 months from the ReS-time (10% vs 33% for <2 and >2 months, P = 0.006). 
The proposed TT staging system can adequately describe the post-LT recurrence, especially in the 
LRC and HRC patients. The intermediate-risk-class needs to be better defined and further studies 
on its ability in defining intention-to-treat survival (ITT) and drop-out are required. 
Keywords: liver transplantation; hepatocellular carcinoma; transplantable tumor 
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1. Introduction 
Over the past twenty years, physicians’ belief in the curative potential of liver transplantation 
(LT) for early hepatocellular carcinoma (HCC) on liver cirrhosis has been strongly reinforced, 
particularly in centers where LT is an available alternative of cure [1–5]. The choice of the best 
candidates and the decision of whether to list a patient for transplantation is currently a field of 
research worldwide. Patients are currently selected and prioritized on specific and validated criteria 
(Milan Criteria, BCLC criteria, UCSF criteria, etc.) [5–7]. Before eventual LT, potential candidates are 
treated with various neo-adjuvant therapies to either downsize tumors or to decrease the risk of 
tumor progression and recurrence [8]. 
Three main concepts may guide the philosophy of listing and assigning priority for a patient 
waiting for LT: utility, urgency, and survival benefit. Accordingly, several models have been 
proposed to date [9–13]. However, it should be noted that relying solely on tumor burden and/or 
alpha-fetoprotein (AFP) cannot fully figure the biological aggressiveness of HCCs. That is, patients 
with the same tumor stage may have a different risk of dropout from the waiting list or of tumor 
recurrence after transplant. This could well be the consequence of both the possibility of offering 
patients neo-adjuvant surgical and loco-regional treatments (LRTs) and on the efficacy of these 
treatments [8,14]. 
Recently, a comprehensive assessment of patients affected by HCC and suitable for transplant 
was proposed by Mazzaferro V. [15] and subsequently included into the Italian Consensus-Based 
Approach to Organ Allocation in Liver Transplantation [16]. Such a concept overcomes the limits of 
various staging systems published to date, by simply defining HCCs as transplantable or not. Eight 
classes of transplantable tumor (TT) were identified through the combination of tumor stage, 
suitability for LRTs, and tumor response to those treatments. To date, despite such conceptual system 
was incorporated within Italian consensus, its validation has never been assessed whereas it should 
be fundamental when developing recommendations. 
The aims of the present study were to apply such a TT staging to evaluate post-LT HCC 
recurrence and survival, as well as to evaluate its suitability in describing different probabilities of 
drop-out. With these aims, the present study constitutes the first effort of validation of the proposed 
assessment which could be useful to identify those candidates who deserve prioritization for LT and 
within which time-frame. 
2. Results 
From January 2005 to December 2015, 376 patients were candidates for LT because of HCC on 
liver cirrhosis (Table 1). Figure 1 reports the patients’ course from the time of listing, through re-
staging (ReS-time) to LT or dropout. Of these, 330 were transplanted and 46 patients dropped-out 
because of tumor progression (27 cases) or other reasons (19 cases) during follow-up. 
Table 1. Listed patients’ characteristics (N = 376). 
 Transplanted PTs 
1 
(N = 330) 
Dropped-Out PTs 
2 (N = 46) 
Total PTs 
(N = 376) 
Characteristics of PTs     
Age, median (IQR)  57 (52–61) 57 (52–60) 57 (52–61) 
Sex, N (%) Men 289 (88) 38 (83) 327 (87.0) 
 Women 41 (12) 8 (17) 49 (13.0) 
Presence of HCV, N (%)  205 (62) 31 (67) 236 (62.8) 
Presence of HBV, N (%)  79 (24) 11 (24) 90 (23.9) 
Abuse of alcohol, N (%)  95 (29) 8 (17) 103 (27.4) 
Other cause of cirrhosis, N (%) 3  17 (5) 2 (4) 19 (5.1) 
Reason for drop-out, N (%) 
HCC 
progression 
 27 (59) 27 (59) 
 Other 4  19 (41) 19 (41) 
Parameter at the last restaging     
Restaging, N (%) TT0C 6 (2) 2 (4) 8 (2.1) 
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 Transplanted PTs 
1 
(N = 330) 
Dropped-Out PTs 
2 (N = 46) 
Total PTs 
(N = 376) 
 TT0L 93 (28) 11 (24) 104 (27.7) 
 TT1 9 (3) 3 (6) 12 (3.2) 
 TT0NT 15 (4) 0 (0) 15 (4.0) 
 TTFR 32 (10) 7 (15) 39 (10.4) 
 TTUT 16 (5) 0 (0) 16 (4.3) 
 TTPR 80 (24) 10 (22) 90 (23.9) 
 TTDR 79 (24) 13 (28) 92 (24.5) 
AFP (ng/mL), median (IQR)  8 (3–35) 35 (5–208) 9 (3–43) 
Missing  31 21 52 
Number of nodules, median (IQR)  1 (0–2) 3 (1–5) 1 (0–2) 
Missing  25 22 47 
Diameter of the largest nodule 
(mm), median (IQR) 
 17 (14–23) 30 (14–45) 18 (14–25) 
Missing  19 3 22 
Time from the last TRT to restaging 
(days), median (IQR) 
 92 (44–245) 97 (37–294) 92 (42–257) 
Missing  14 0 14 
MELD score, N (%) ≤9 105 (32) 3 (18) 108 (31.4) 
 10–19 193 (60) 10 (59) 203 (58.8) 
 20–29 25 (7) 3 (18) 28 (8.1) 
 ≥30 3 (1) 1 (5) 6 (1.7) 
 Missing 2 29 31 
CHILD score, N (%) A 152 (51) 4 (36) 156 (50.5) 
 B 112 (38) 3 (27) 115 (37.2) 
 C 34 (11) 4 (36) 38 (12.3) 
 Missing 32 35 67 
Tumor classification, N (%) T0 103 (35) 3 (14) 106 (33.7) 
 T1–T2 160 (55) 7 (32) 167 (53.0) 
 T3–T4 30 (10) 12 (54) 42 (13.3) 
 Missing 37 24 61 
TRT, N (%) Yes 273 (83) 42 (91) 315 (83.8) 
Parameters and pathology at LT  
AFP (ng/mL), median (IQR)  8 (4–24)  8 (4–24) 
Missing  35  35 
Number of nodules, median (IQR)  2 (1–3)  2 (1–3) 
Diameter of the largest nodule 
(mm), median (IQR) 
 20 (15–30)  20 (15–30) 
Grade of HCC, N (%) 0 36 (12)  36 (12) 
 1 34 (11)  34 (11) 
 2 148 (48)  148 (48) 
 3 93 (29)  93 (29) 
 Missing 15  15 
Microvascular invasion, N (%) No 218 (73)  218 (73) 
 Yes 82 (27)  82 (27) 
 Missing 30  30 
Macrovascular invasion, N (%) No 289 (97)  289 (97) 
 Yes 9 (3)  9 (3) 
 Missing 32  32 
PTs: patients, IQR: interquartile range, DG: diagnosis, LT: transplant. 1 Low risk: 108, intermediate 
risk: 63, high risk: 159. 2 Low risk: 16, intermediate risk: 7, high risk: 23. 3 Other causes of cirrhosis 
include: CRIPTO, HDV, HIV, emacromatosis, Wilson disease, sclerosing cholangitis, cholangitis 
primary biliary and secondary biliary cholangitis; 4 other cancers, chronic diseases, spontaneous 
regression of HCC. 
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Figure 1. Management of patients with hepatocellular carcinoma (HCC) from listing to HCC relapse 
in a multi-state framework. The lines connecting the boxes (states) represent the four transitions of 
interest (i.e., from listing to restaging, from restaging to liver transplant, from restaging to HCC 
progression w/o liver transplant, and from liver transplant to HCC recurrence). 1 The date of liver 
transplant is the starting time for the estimation of cumulative incidence function (CIF) of HCC 
recurrence after liver transplant (LT) (Figure 2, Figure 4). 2 The date of restaging is the starting time 
for the estimation of CIF of LT (Figure 3A) or HCC progression without LT (Figure 3B). 3 The date of 
listing is the starting time for the estimation of intention-to-treat survival function (Figure S1A) and 
CIF of HCC recurrence or progression (Figure S1B). 4 N = 19 patients dropped-out for other causes 
than HCC progression (19/1274 p-m (person-month) = 0.015 ways out from list/months). 
2.1. Impact of Re-Staging Features on Post LT Outcome 
The 330 transplanted patients were classified at the ReS-time into: HRC for 159 (48.2%); IRC for 
63 (19.1%); and LRC for 108 (32.7%). Characteristics of transplanted patients are detailed in the Table 
S1. In summary, at listing the IRC candidates had higher number of HCCs and the LRC had smaller 
tumors, so that the final T-stage at listing resulted more advanced in the IRC group than the HRC 
and LRC (P < 0.0001). Intermediate-risk class patients had more compromised liver function, as 
depicted by higher MELD score. At ReS-time, HRC had more advanced tumors, as excepted. Finally, 
the pathological evaluation of the explanted livers revealed more numerous and larger nodules in 
the IRC and HRC groups (P < 0.0001) and the prevalence of G3 tumors and microvascular invasion 
were significantly higher in the HRC group (P < 0.0001 for both). 
On this ground, 51 tumor recurrences were observed among the 330 transplanted patients. The 
overall cumulative incidences of tumor recurrence after LT at 5 and 10 years respectively were 15% 
and 20% (Figure 2A). The 5-year recurrence rates were 21% in HRC, 12% in IRC, and 8% in LRC 
(Figure 2B; P = 0.011). The 5-year overall post-LT survival was 78% (95% CI: 73–82%). 
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Figure 2. Cumulative incidence of HCC recurrence after liver transplantation overall (A) and by 
priority (B) (N = 330). 
Hepatitis B or Hepatitis C as underlying diseases were not associated to a significant different 
cumulative HCC recurrence after transplant (Figure S1). 
Tumor recurrence was found to be related not only to the risk-class at re-staging but also to the 
time elapsed from re-staging to LT. In particular, IRC patients showed a significantly lower 
cumulative incidence (95% CI) of 5-year tumor relapse after LT if the interval between times ReS-time 
and LT-time was ≥2 months (3% (0.2–15%) vs 28% (9–50%) when <2 months; P = 0.031). Conversely, 
HRC patients had a significantly lower cumulative incidence of 5-year tumor relapse after LT if 
transplanted within 2 months from the ReS-time (10% (4–19%) vs 33% (22–45%) when ≥2 months; P 
= 0.006) (Figure 3). 
 
Figure 3. Cumulative incidence of HCC recurrence after liver transplantation for (A) low, (B) 
intermediate and (C) high risk stratified between transplanted patients within 2 months and after 2 
months from restaging (N = 330). 
High-risk class and alpha-fetoprotein at the Re-S-time resulted independently related to tumor 
recurrence after LT: HR = 2.89 (95% CI: 1.26–6.64; P = 0.012) and HR = 1.23 (95% CI: 1.10–1.37; P = 0.0002), 
respectively (Table 2). The alpha-fetoprotein level and pathological features at the LT-time were not 
significantly different among patients transplanted within 2 months or after 2 months from the ReS-
time both in the IRC and HRC groups. The only significant different feature was the median diameter 
of the largest nodule in the IRC group, which was larger among patients transplanted ≥2 months (20 mm 
vs 26 mm, P = 0.04) (Table 3). 
Table 2. Association between patient or tumor characteristics and the risk of HCC recurrence after 
LT. (N = 330). Hazard ratios estimated using Fine and Gray proportional hazards models, considering 
death w/o HCC as first event as a competitive event. 
 
Univariate Model Multivariate Model 
HR (95% CI) P HR (95% CI) P 
Priority     
Low risk Ref.  Ref.  
Intermediate risk 1.23 (0.47–3.19) 0.67 1.56 (0.51–4.74) 0.43 
High risk 2.60 (1.28–5.26) 0.0079 2.89 (1.26–6.64) 0.012 
Age (years)     
+10 years increase 0.91 (0.57–1.43) 0.67 0.93 (0.57–1.51) 0.77 
Sex     
Women Ref.  Ref.  
Men 0.90 (0.41–2.01) 0.80 0.93 (0.49–1.76) 0.81 
AFP at the last restaging (ng/mL)     
Doubling the AFP value 1.22 (1.10–1.35) <0.0001 1.23 (1.10–1.37) 0.0002 
Number of nodules at the last restaging     
+1 nodule 1.24 (1.04–1.9) 0.018   
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Diameter of the largest nodule at the last restaging (mm)     
+1 mm increase 1.03 (1.00–1.06) 0.026   
MELD score at the last restaging     
+1 pt increase 0.95 (0.89–1.02) 0.19 0.98 (0.90–1.07) 0.72 
Tumor classification at the last restaging     
T0 Ref.    
T1–T2 1.79 (0.89–3.59) 0.10   
T3–T4 4.26 (1.83–9.96) 0.0008   
Time to LT from the last restaging     
<2 months Ref.  Ref.  
≥2 months 1.25 (0.71–2.22) 0.44 1.25 (0.66–2.38) 0.50 
HR: hazard ratio, LT: transplant, Ref.: reference category. 
Table 3. Comparison between intermediate and high-risk patients transplanted within 2 months from 





P 1 <2 months  
(N = 22) 
≥2 months (N = 41) <2 months (N = 78) ≥2 months (N = 81) 
AFP at LT, median (IQR) 12 (3–32) 6 (4–12) 0.24 9 (5–25) 11 (4–39) 0.43 
Number of nodules, median (IQR) 2 (1–4) 2 (1–3) 0.73 2 (1–3) 2 (1–4) 0.32 
Diameter of the largest nodule, median (IQR) 20 (15–28) 26 (20–35) 0.04 25 (15–30) 25 (18–30) 0.45 
Macrovascular invasion, N (%)      0.49 
No 21 (100) 36 (100)  72 (96) 72 (94)  
Yes 0 (0) 0 (0)  3 (4) 5 (6)  
Microvascular invasion, N (%)   0.85   0.35 
No 16 (80) 28 (78)  50 (65) 45 (58)  
Yes 4 (20) 8 (22)  27 (35) 33 (42)  
Grading, N (%)   0.36   0.87 
0 1 (5) 2 (5)  5 (6) 3 (4)  
1 4 (19) 4 (10)  5 (6) 6 (7)  
2 14 (67) 22 (57)  38 (50) 39 (49)  
3 2 (9) 11 (28)  29 (38) 32 (40)  
IQR: interquartile range, LT: transplant. 1 Wilcoxon test’s P-value for continuous variables, Chi-square 
test’s P for categorical variables. 
2.2. Dropped-Out From WL 
A total of 46 patients dropped out in a median time of 209 days (IQR: 104–369 days) from listing 
and 132 days (IQR: 49–195 days) from ReS-time. Among these, 16 were in LRC (35%), 7 in IRC (15%), 
and 23 in HRC (50%) at ReS-time. The majority of dropped-out patients had tumor progression (27/46, 
59%), whereas 19/46 (41%) patients were excluded from LT for other reasons (Table 1). 
2.3. Intention-to-Treat and Survival 
Reconsidering the whole study population of 376 patients, the 5-year intention-to-treat survival 
(ITTs) was 70% (95% CI: 64–74%), from listing (Figure S2). Since the ReS-time, patients had a 
cumulative incidence of transplant at 1-year (95% CI) of 89% (85–92%) and a cumulative incidence of 
tumor progression without LT at 1-year (95% CI) of 7% (5–10%) (Figure 4). 
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Figure 4. Cumulative incidence of liver transplantation (A) and HCC progression w/o liver 
transplantation (B) calculated from restaging, overall and by priority (N = 376). 
Figure 4 showed no statistically significant difference in the cumulative incidence of LT or tumor 
progression without transplant among the three groups; however, the curves showed a trend 
towards higher incidences (of LT and tumor progression) in the higher-risk patients’ class. 
3. Discussion 
To the best of our knowledge, this is the first effort to validate the new comprehensive 
assessment of transplantable tumor (HCC) adopted in the Italian Consensus-Based new allocation 
system [16]. The present study consisted of an a posteriori application of the proposed TT staging. 
The opportunity to validate this new staging on a patient cohort treated before its proposal should 
reinforce the obtained results. Indeed, although patients were selected for LT and prioritized based 
on different criteria throughout the study time (2005–2015), we observed a linear trend between the 
probability of receiving a LT or dropping out secondary to tumor progression and the severity of the 
TT class. This correlation, however, was not statistically significant. 
Patients classified into the HRC group (TTDR and TTPR) had higher incidence of both being 
transplanted and dropping than those in the IRC and LRC groups. Moreover, HRC re-staged patients 
had a significantly higher risk of tumor recurrence after transplant, particularly if they were 
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transplanted later than 2 months from the ReS-time. Several authors have previously suggested that 
the worst outcomes are observed when down-staging treatments prior to LT are not fully effective, 
namely higher incidences of tumor recurrence after transplant or dropouts without transplant 
[14,17,18]. The HRC group included patients with tumor progression after downstaging (TTDR) or 
patients who had a partial tumor response after LRTs (TTPR). Related to these two categories of 
patients, this study suggested that a high priority to LT (possibly within 2 months from ReS-time) 
may significantly reduce the risk of tumor recurrence after LT. In other words, the sooner the HRC 
patients are transplanted, the lower their tumor recurrence rates will be. Although patients in the 
HRC group received the same LRTs regimens as the other patients, they did not show a complete 
response to LRTs, this could probably be explained by tumor proper characteristics (i.e., 
vascularization, location, cell differentiation). However, if these patients were transplanted within 2 
months from ReS-time, their tumor cumulative incidence after-LT appeared to be similar to the other 
groups (<10% at 5 years). We therefore hypothesize that, for these patients a short interval between 
ReS-time and LT-time may be the key to significantly decrease the rate of post-LT tumor recurrence, 
by the chance of higher priority or living donor LT. 
Surprisingly on the other hand, a too fast-track from ReS-time to LT for patients classified as IRC 
(TT0NT, TTFR, and TTUT) may be associated with worse tumor-related results. These patients belong to 
successful downstaging, or HCC > T1 at the first presentation or late recurrent HCC after curative 
treatments and those patients judged untreatable for reasons not captured by MELD. In the present 
study the tumor T-stage of IRC patients at the listing appeared to be worse than the other two groups. 
Despite that, after the successful application of downstaging and bridging treatments, the 
radiological staging at the ReS-time demonstrated a significant downgrading of the tumor stage for 
IRC with lower T-stage compared to the HRC group, as expected. However, despite the effective 
tumor downsizing among these patients, their post-LT 5-year cumulative recurrence rate was up to 
28% for those transplanted within 2 months since the ReS-time but, more importantly, 3% for those 
transplanted later. If compared to findings in the HRC, the present one is not paradoxical as it seems 
and was simply related to the fact that this risk category had the highest prevalence of untreated 
candidates: for these cases, the “test-of-time” dominates the clinical outcome. In fact, some authors 
have recently pointed out the risk of bringing patients too fast to LT [17–21]. Halazun K. and co-
workers reported a significantly lower long-term survival among HCC patients transplanted within 
less than 2 months from the time of listing in the United States [22]. The authors provided evidence 
that expediting HCC patients to LT at too fast a rate may adversely affect patient outcomes. The 
adverse effect of the “fast track” was explained by the fact that these patients are more likely to be 
undertreated before LT as well as by the lack of a test-of-time. The concept of “test-of-time” could be 
understood as a minimal period between two surveillance time points (imaging, lab values, clinical 
evaluation) that may help distinguish patients with aggressive diseases that progress quickly, a 
surrogate marker of an aggressive tumor biology, therefore distinguishing patients who need to be 
prioritized from those who need to be excluded. In our study, the time interval between the last LRTs 
and ReS-time was shorter in the IRC compared to the other classes. Although not statistically 
significant, perhaps IRC patients need a longer interval to better assess the tumor response to LRTs. 
A few years ago, several authors pointed out the risk of worse tumor-related results of LT from 
a living donor (LDLT) than from a deceased one [21,23–25]. The proposed hypotheses included: more 
advanced tumors treated with LDLT and hyper-inflow in a partial transplanted liver as a 
cancerogenetic promoter. Several authors demonstrated higher tumor recurrences after LDLT, even 
after adjusting for tumor stage selection before LT [21,23–25]. In clinical practice, the availability of a 
living donor for an HCC patient may discourage physicians from spending time downgrading 
tumors before transplant; therefore, in some series the rate of patients undergoing LRTs before LDLT 
is very low while tumor recurrence after LT is high [21,23–25]. In that sense, IRC represents a group 
of patients wherein considering LDLT may be risky due to the probability to go too fast to transplant 
instead of obtaining a test-of-time for a better assessment of tumor biology. On the other hand, the 
HRC group may strongly benefit from an early transplant from the ReS-time, an available living 
donor for those patients may therefore represent the best chance. 
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The LRC group did not show any correlation with tumor stages and recurrence after LT. Patients 
included in the LRC group were generally transplanted before the time may adversely affect 
transplant results without differences among patients transplanted before or after 2 months from 
ReS-time. The LRC group does not usual pose a crucial management dilemma for physicians, 
however those patients should be under surveillance according to the international guidelines [19]. 
The presented results are limited by the retrospective nature of the study. The clinically-based 
construction of the three risk classes is also limited by the patient cohort size and some of the missing 
data. The lack of a validation cohort can further weaken our results. We should however hasten to 
add that the present study was not planned to produce a new prognostic system, rather to verify 
whether patients can be stratified using the present conceptual framework. As we previously stated, 
such a framework is currently adopted in the Italian Consensus-Based allocation system and we 
needed to analytically verify whether corrective maneuvers are necessary. We observed in fact, that 
IRC patients need to be better identified and we hope that our findings could be taken into account 
in the future national consensus. In addition, to provide a strong clinical application of the TT system 
it will be necessary to compare current prognostic ability to that of already developed staging systems 
in order to find the best tool to adopt. Further studies in this sense represent the next steps since 
present one. 
4. Materials and Methods 
This is a single-center retrospective study using a prospectively maintained database, including 
all consecutive patients who were candidate for LT for HCC on liver cirrhosis between January 2005 
and December 2015. The Institutional Ethical and Scientific board approved the present study. 
Pre-operative diagnosis of HCC was made according to non-invasive European Association for 
the Study of the Liver (EASL) criteria [4]. In cases lacking conclusive radiological diagnosis, 
ultrasound-guided biopsy was used [19]. All the cases were discussed in a multidisciplinary meeting 
with surgeons, hepatologists, radiologists, and anesthesiologists. Patients were followed up for life 
and received surveillance for the risk of new HCC diagnosis according to the EASL guidelines [19]. 
Patients were selected for transplant based on the Milan Criteria [6] until 2008 and based on the 
up-to-seven criteria from 2009 until 2015 [9]. Patients with a tumor stage beyond selection criteria at 
diagnosis were listed for LT only after an effective down-staging. Indications for down-staging and 
for HCC bridging treatments during the waiting period to transplantation were previously published 
[14,26]. All patients treatable by LRTs were treated prior to transplant. Extra-hepatic tumor, macro-
vascular invasion, and age >70 years were contraindications for LT in our center. Tumor response to 
the LRTs was prospectively assessed by the modified RECIST (Response evaluation criteria in solid 
tumors) criteria since their release, and retrospectively for cases before 2010 [27–29]. 
The policy for organ allocation was already detailed elsewhere [30,31]. 
All potential HCC candidates routinely underwent imaging re-assessment (tumor re-staging) 
approximately every 3 months; therefore, their priority was clinically re-assessed based on new 
radiological findings, liver function, and general clinical conditions. The present study was designed 
to evaluate the prognostic prediction of the TT staging system [15,16] as summarized in Figure 1. The 
re-staging time (ReS-time) used in the present study corresponded to the last available prior to LT or 
removal from the waiting-list (drop-out). At this landmark temporal endpoint, patients were 
classified into one of the following classes: TT0C, no residual tumor after curative treatment of HCC; 
TT0L, no residual tumor after locoregional embolo-therapies for transplantable HCC; TT1, single HCC 
≤2 cm; TT0NT, no residual tumor after treatment of a non-transplantable HCC (successful 
downstaging); TTFR, transplantable HCC >T1 at first presentation or recurrent HCC >2 years after 
curative treatment; TTUT, transplantable HCC judged untreatable for reasons not captured by MELD 
(i.e., ascites); TTPR, partial response after complete bridge therapy in a transplantable tumor; TTDR, 
transplant eligibility after downstaging (sustained partial response) or recurrent HCC <2 years after 
curative treatment of any HCC. The 8 classes described were combined into three larger classes based 
on clinical evaluation of the tumor progression risk before LT and tumor recurrence risk after LT: 
• High-risk-class (HRC) = stages TTDR and TTPR; 
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• Intermediate-risk-class (IRC) = stages TT0NT, TTFR, and TTUT; 
• Low-risk-class (LRC) = stages TT1, TT0L, and TT0. 
Statistical Analysis 
Continuous data are reported as median and interquartile ranges (IQR) and categorical data as 
counts and percentages (%). Associations between continuous or categorical variables were evaluated 
using Wilcoxon test and Chi-square test, respectively. Survival functions were estimated using the 
Kaplan–Meier method. The cumulative incidences of being transplanted and of HCC progression 
without being transplanted were calculated from the time of restaging until the considered event. 
Drop-out from the waiting list due to other causes than HCC progression was considered as a 
competing event. 
In transplanted patients, the cumulative incidence of HCC recurrence was calculated from the 
time of transplant until the evidence of recurrence. Death for causes unrelated to HCC was 
considered as a competing event, while patients alive and recurrence-free at time of the analysis were 
censored. Cumulative incidence functions were estimated according to the method described by 
Kalbfleisch and Prentice [32]. The Gray’s test [33] was used to assess cumulative incidence differences 
between groups. 
Univariable and multivariable Fine and Gray proportional-hazards models [34], taking the 
competing risk of death for causes unrelated to HCC into account, were used to evaluate the effects 
on HCC recurrence of the time elapsed from the date of the last ReS and LT (categorized as less than 
two months and greater than or equal two months) and of the following variables evaluated at last 
ReS time: risk class (low, intermediate, or high), age, sex, AFP (ng/mL), number of nodules, diameter 
of the largest nodule, MELD score, tumor classification. The “2 months” cutoff has been choose basing 
on the median interval resulted between ReS-time and LT-time and basing on the general time 
needed to perform a living donor LT since the listing time [22]. In the final multivariable model, the 
number of nodules, the diameter of the largest nodule and the tumor classification at last ReS were 
not considered as independent variables because of their association with the risk classification 
assigned at the ReS-time. A P value <0.05 was considered statistically significant for all analyses. All 
the analyses were performed with the use of SAS software, version 9.4 (SAS Institute, Cary, North 
Carolina, USA). 
5. Conclusions 
In conclusion, the comprehensive assessment of TT stage seems to be effective in classifying 
patients into different groups and predicting tumor recurrence rates after transplant. The drop-out 
risk of patients evaluated at ReS-time seems to be proportional to the risk class assigned, moreover 
HRC is an independent risk factor for higher tumor recurrence rates after transplant. While a shorter 
time-to-transplant (< or ≥2 months after ReS-time) may play a favorable role for HRC, it negatively 
affects IRC patients. The IRC class needs to be explored much deeper, specially concerning 
differences between treated and untreated candidates’ stages. Our results suggest that physicians 
need to treat patients as much as possible before the ReS-time and to give them a priority based on 
the different TT stages. Finally, LDLT, when available, may guarantee a shorter and safer track for 
HRC. Further validation may be needed to reinforce these findings. 
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